Delta sleep inducing peptide promises exactly what its name says: sleep, and specifically the deep, slow-wave kind. The strongest human trial behind that promise is a single double-blind study from 1992, in 16 chronic insomniacs, and it barely moved the needle. The most solid modern human finding about DSIP is not about sleep at all. It is that DSIP reliably suppresses a stress hormone, in healthy men who were not insomniacs, with a precision the sleep data has never come close to matching.
That contrast is the story. A peptide named for one effect has its best evidence for a different one entirely.
What the small human sleep trials found
DSIP was isolated by 1977. As Schoenenberger later summarized it, the work grew out of experiments dialyzing the venous blood of rabbits kept asleep through electrical stimulation of the thalamus, which is where the somewhat literal name comes from.[1] His group characterized and synthesized the resulting nonapeptide over the following years.
The only double-blind, placebo-controlled human trial specifically testing DSIP against insomnia is small and old. Bes and colleagues gave 16 chronic insomniac patients intravenous DSIP or a glucose placebo before three consecutive nights in a sleep laboratory.[2] The results were not encouraging:
Objective sleep efficiency and latency improved somewhat with DSIP, but the effect was statistically weak.
Part of that weak effect was traceable to an incidental change in the placebo group rather than a clean DSIP effect.
Subjective sleep quality, the thing an insomniac cares about most, showed no significant difference from placebo.
The authors concluded that short-term DSIP treatment was not likely to be of major therapeutic benefit. Nobody has published a larger confirmatory trial since.
One trial, one design, and what it does and doesn’t prove
The Bes trial used a controlled interventional design: a fixed dose, then measured outcomes. That kind of design can support a causal read of short-term effects, but only within the 16 people it tested. It says nothing about a broader insomniac population, and no one has run the larger, adequately powered, placebo-controlled trial that would.
No published trial has tested whether DSIP treats a diagnosed sleep disorder at any scale beyond that single study. Marketing claims that DSIP “resets” or “restores” the sleep cycle go well beyond anything an interventional trial has measured. That is not a regulatory quibble. It is a claim with no trial behind it.
The clearest human finding has nothing to do with sleep
Here is the part that gets skipped in most DSIP writeups. The two best-designed human trials of DSIP were not sleep studies. They tested its effect on stress hormones.
In a double-blind, placebo-controlled, crossover trial, Bjartell and colleagues gave a single intravenous dose of DSIP (25 nmol/kg) to 11 healthy men and found it significantly reduced circulating ACTH for at least three hours compared to saline, while plasma cortisol stayed on its normal daily pattern.[3] The authors called it an inhibitory action on ACTH secretion in man, matching what animal work had already suggested.
3 hours+ how long a single DSIP dose suppressed ACTH in healthy men PMID 2554357
Chiodera and colleagues then tested whether that effect was specific. In normal men, DSIP again produced a significant drop in ACTH, but it did not change circulating arginine-vasopressin under resting conditions, after an osmotic challenge, or after an orthostatic (standing) test.[4] The inhibition is targeted at ACTH. It is not a blanket dampening of everything the pituitary releases.
The most reproducible human finding about DSIP is that it blunts ACTH release, confirmed in two separate trials a few years apart.[3][4] Neither trial tested whether it helps anyone sleep.
Mechanism: confirmed pharmacology versus hopeful guesses
As of a 1986 literature review by Graf and Kastin, DSIP’s mechanism of action, including a proposed role in modulating adrenergic transmission, had not been established.[5] That gap has not closed. No source in this piece’s citation list identifies a specific DSIP receptor, in the brain or anywhere else, that would explain a direct sleep-regulating action.
Some researchers have floated DSIP as more of a stress-modulating or homeostatic peptide than a dedicated sleep hormone. Given the ACTH data above, that framing looks better supported by what has been measured in humans than the sleep-inducing story the name sells. It is also worth being honest about a gap: animal work is often cited as evidence that DSIP acts on the broader hypothalamic-pituitary-adrenal axis, but no source in this article’s citation list tests that pathway directly in animals. The real evidence on the endocrine front is the human data above, not the animal claims that get repeated around it.
Pharmacokinetics: gone in minutes
Whatever DSIP does, it does not do it for long. Kato and colleagues developed an immunoassay to track DSIP clearance after intravenous injection in dogs, a monkey, and rats.[6] The peptide disappeared from plasma fast.
DSIP plasma half-life by species
Species | Mean half-life |
|---|---|
Dogs | 4.0 ± 0.7 min |
Monkey | 2.9 min |
Rats | 2.0 ± 0.54 min |
Kato et al 1984, intravenous administration.
A peptide that clears in a few minutes is a poor candidate for an all-night sleep effect delivered by a single injection, which is one plausible reason the human sleep trials produced such inconsistent results.
What we don’t know about safety
No dedicated safety data for DSIP survived verification for this piece. That absence is itself worth stating plainly: it means the “well-tolerated” reputation the compound carries in research-chemical marketing is not backed, in this citation list, by a modern, closely monitored trial designed to catch adverse events.
No regulatory agency has approved DSIP for any medical use. It is currently sold as an unregulated research chemical, without the standardized manufacturing oversight that a licensed pharmaceutical goes through.
Nothing in this article’s citation list is a modern, closely monitored safety trial of DSIP. The compound’s “well-tolerated” reputation rests on studies old enough to predate the safety-monitoring standards a trial would use today.
Where DSIP sits next to better-studied sleep compounds
Put DSIP next to the compounds people compare it to, and the gap is stark. Melatonin and the hypnotic medications people use for insomnia have large, modern, randomized trial bases behind them. DSIP’s entire sleep evidence is a handful of small, mid-twentieth-century studies that were never followed up.
The same pattern shows up across other peptides marketed with thin backing, as covered in our look at the human evidence gap behind GHK-Cu injections and our broader survey of which peptide claims have human trials behind them. Growth-hormone-axis peptides tell a different story. Tesamorelin has real, modern human trial data behind it. DSIP has not been revisited with contemporary trial methodology since researchers moved on from it decades ago.
What a credible trial would need to look like
The bulk of DSIP research dates from the late 1970s through the 1990s. Comparatively little new investigation has been published in recent decades, which is unusual for a compound with this much name recognition in longevity and biohacking circles.
Reviving a real case for DSIP as a sleep treatment would take an adequately powered, placebo-controlled trial using objective polysomnography, not the subjective sleep diaries and small samples the existing literature leans on.
Bottom line: DSIP has real, reproducible pharmacology. It suppresses ACTH in healthy men, twice confirmed, and it clears from plasma within minutes. What it does not have is a modern, adequately powered trial showing it improves sleep. Until that trial exists, DSIP remains a compound with strong endocrine data and no real sleep data, a distinction its own name was built to obscure.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP).. European neurology, 1984.
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.. Neuropsychobiology, 1992.
Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man.. Psychoneuroendocrinology, 1989.
Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men.. Hormone research, 1994.
Delta-sleep-inducing peptide (DSIP): an update.. Peptides, 1986.
Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs.. Neuroendocrinology, 1984.
